Literature DB >> 17142322

Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange.

Norbert Weissmann1, Alexander Dietrich, Beate Fuchs, Hermann Kalwa, Mahmut Ay, Rio Dumitrascu, Andrea Olschewski, Ursula Storch, Michael Mederos y Schnitzler, Hossein Ardeschir Ghofrani, Ralph Theo Schermuly, Olaf Pinkenburg, Werner Seeger, Friedrich Grimminger, Thomas Gudermann.   

Abstract

Regional alveolar hypoxia causes local vasoconstriction in the lung, shifting blood flow from hypoxic to normoxic areas, thereby maintaining gas exchange. This mechanism is known as hypoxic pulmonary vasoconstriction (HPV). Disturbances in HPV can cause life-threatening hypoxemia whereas chronic hypoxia triggers lung vascular remodeling and pulmonary hypertension. The signaling cascade of this vitally important mechanism is still unresolved. Using transient receptor potential channel 6 (TRPC6)-deficient mice, we show that this channel is a key regulator of acute HPV as this regulatory mechanism was absent in TRPC6(-/-) mice whereas the pulmonary vasoconstrictor response to the thromboxane mimetic U46619 was unchanged. Accordingly, induction of regional hypoventilation resulted in severe arterial hypoxemia in TRPC6(-/-) but not in WT mice. This effect was mirrored by a lack of hypoxia-induced cation influx and currents in smooth-muscle cells from precapillary pulmonary arteries (PASMC) of TRPC6(-/-) mice. In both WT and TRPC6(-/-) PASMC hypoxia caused diacylglycerol (DAG) accumulation. DAG seems to exert its action via TRPC6, as DAG kinase inhibition provoked a cation influx only in WT but not in TRPC6(-/-) PASMC. Notably, chronic hypoxia-induced pulmonary hypertension was independent of TRPC6 activity. We conclude that TRPC6 plays a unique and indispensable role in acute hypoxic pulmonary vasoconstriction. Manipulation of TRPC6 function may thus offer a therapeutic strategy for the control of pulmonary hemodynamics and gas exchange.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142322      PMCID: PMC1748182          DOI: 10.1073/pnas.0606728103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Hypoxic pulmonary vasoconstriction: a multifactorial response?

Authors:  N Weissmann; F Grimminger; A Olschewski; W Seeger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-08       Impact factor: 5.464

Review 2.  Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension.

Authors:  T K Jeffery; J C Wanstall
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

3.  Cyclic ADP-ribose is the primary trigger for hypoxic pulmonary vasoconstriction in the rat lung in situ.

Authors:  M Dipp; A M Evans
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

Review 4.  The diacylgylcerol-sensitive TRPC3/6/7 subfamily of cation channels: functional characterization and physiological relevance.

Authors:  Alexander Dietrich; Hermann Kalwa; Benjamin R Rost; Thomas Gudermann
Journal:  Pflugers Arch       Date:  2005-06-22       Impact factor: 3.657

5.  NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs.

Authors:  N Weissmann; S Winterhalder; M Nollen; R Voswinckel; K Quanz; H A Ghofrani; R T Schermuly; W Seeger; F Grimminger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-04       Impact factor: 5.464

6.  Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction.

Authors:  S S McDaniel; O Platoshyn; J Wang; Y Yu; M Sweeney; S Krick; L J Rubin; J X Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-05       Impact factor: 5.464

7.  Divergent roles of glycolysis and the mitochondrial electron transport chain in hypoxic pulmonary vasoconstriction of the rat: identity of the hypoxic sensor.

Authors:  R M Leach; H M Hill; V A Snetkov; T P Robertson; J P Ward
Journal:  J Physiol       Date:  2001-10-01       Impact factor: 5.182

8.  Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing.

Authors:  G B Waypa; N S Chandel; P T Schumacker
Journal:  Circ Res       Date:  2001-06-22       Impact factor: 17.367

9.  Effects of hypoxia in porcine pulmonary arterial myocytes: roles of K(V) channel and endothelin-1.

Authors:  J S Sham; B R Crenshaw; L H Deng; L A Shimoda; J T Sylvester
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-08       Impact factor: 5.464

10.  The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.

Authors:  R Inoue; T Okada; H Onoue; Y Hara; S Shimizu; S Naitoh; Y Ito; Y Mori
Journal:  Circ Res       Date:  2001-02-16       Impact factor: 17.367

View more
  123 in total

1.  Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.

Authors:  Tom Nijenhuis; Alexis J Sloan; Joost G J Hoenderop; Jan Flesche; Harry van Goor; Andreas D Kistler; Marinka Bakker; Rene J M Bindels; Rudolf A de Boer; Clemens C Möller; Inge Hamming; Gerjan Navis; Jack F M Wetzels; Jo H M Berden; Jochen Reiser; Christian Faul; Johan van der Vlag
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

Review 2.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  TRP channel Ca(2+) sparklets: fundamental signals underlying endothelium-dependent hyperpolarization.

Authors:  Michelle N Sullivan; Scott Earley
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

Review 4.  Transient receptor potential channels as therapeutic targets.

Authors:  Magdalene M Moran; Michael Allen McAlexander; Tamás Bíró; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

5.  TRPA1 channels: expression in non-neuronal murine lung tissues and dispensability for hyperoxia-induced alveolar epithelial hyperplasia.

Authors:  Martina Kannler; Robin Lüling; Ali Önder Yildirim; Thomas Gudermann; Dirk Steinritz; Alexander Dietrich
Journal:  Pflugers Arch       Date:  2018-05-12       Impact factor: 3.657

6.  Superoxide generated at mitochondrial complex III triggers acute responses to hypoxia in the pulmonary circulation.

Authors:  Gregory B Waypa; Jeremy D Marks; Robert D Guzy; Paul T Mungai; Jacqueline M Schriewer; Danijela Dokic; Molly K Ball; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

7.  Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction.

Authors:  Liming Wang; Jun Yin; Hannah T Nickles; Hannes Ranke; Arata Tabuchi; Julia Hoffmann; Christoph Tabeling; Eduardo Barbosa-Sicard; Marc Chanson; Brenda R Kwak; Hee-Sup Shin; Songwei Wu; Brant E Isakson; Martin Witzenrath; Cor de Wit; Ingrid Fleming; Hermann Kuppe; Wolfgang M Kuebler
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 8.  Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem.

Authors:  Jeremy P T Ward; Ivan F McMurtry
Journal:  Curr Opin Pharmacol       Date:  2009-03-16       Impact factor: 5.547

9.  Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells.

Authors:  Gregory B Waypa; Jeremy D Marks; Robert Guzy; Paul T Mungai; Jacqueline Schriewer; Danijela Dokic; Paul T Schumacker
Journal:  Circ Res       Date:  2009-12-17       Impact factor: 17.367

10.  Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.

Authors:  Jian Wang; Kai Yang; Lei Xu; Yi Zhang; Ning Lai; Hua Jiang; Yajie Zhang; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.